Please login to the form below

Not currently logged in

Daiichi Sankyo appoints Jan Van Ruymbeke as European CEO

He will join the company in October from Grünenthal

Jan Van Ruymbeke - Daiichi Sankyo EuropeJan Van Ruymbeke has been appointed CEO of Daiichi Sankyo Europe – the European arm of the Japanese pharma company.

He replaces Reinhard Bauer, who is retiring after 10 years in the position, and will take over in October, 2012.

Van Ruymbeke joins Daiichi from Grünenthal, where he has been executive VP leading the German firm's business in Latin America since July, 2010.

He initially joined Grünenthal in 2005, serving as head of global brand management, before becoming managing director for Spain and Portugal and then assuming his current position.

Prior to his time at Grünenthal, Van Ruymbeke worked at several companies across the world, holding such positions as executive director, pharma and country president at Novartis South Africa and general manager of Janssen-Cilag Hungary.

He began his pharma career with Cilag Belgium, having previously worked for several years as a general practitioner and a medical advisor

Outgoing CEO Bauer said: “We are really pleased that we were able to hire Jan Van Ruymbeke to be the next CEO of Daiichi Sankyo Europe. He has an excellent understanding of the pharmaceutical industry. Thanks to his extensive experience in many countries, he is the ideal candidate to lead Daiichi Sankyo Europe's internationally focused business.”

12th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...